Objective. The aim of this study was to analyse the relationship between glucocorticoids and damage accrual in SLE.
Introduction
SLE is a complex disease with a wide clinical spectrum. Despite the advent of new drugs, glucocorticoids remain the most used therapy for lupus [1] . High doses of prednisone, usually 1 mg/kg/day, are recommended for severe SLE manifestations, however, such recommendations are not evidence based [2, 3] .
Recent studies have identified different dosedependent mechanisms of action of glucocorticoids [2] . The genomic pathway is almost completely saturated at doses of prednisone >30 mg/day [2] . This pathway, more specifically the mechanism known as transactivation, is responsible for most glucocorticoid-related adverse effects. In lupus, glucocorticoids have been related to damage accrual [46] . On the other hand, non-genomic pathways, with more potent and less toxic effects, become active at doses >100 mg/day [3] .
Indirect data suggest that lower doses of prednisone can be used in lupus patients, with pulse methylprednisolone therapy constituting a good option in acute situations [3, 79] . Clinical and pharmacological studies suggest that a safe cut-off for prednisone doses could be around 7.5 mg/day, the limit between low and medium dose [2, 5] . However, more data are needed in order to confirm these observations. This study aimed to analyse the relation between treatment with oral prednisone and damage accrual, both general and domain specific, during the first 5 years of the disease course as measured by the SLICC damage index (SDI) [10, 11] . As a secondary objective, we studied the effects on damage of i.v. pulses of methylprednisolone.
Patients and methods

Patients
All patients were included in the longitudinal LupusCruces cohort at the Autoimmune Diseases Research Unit, Hospital Universitario Cruces, University of the Basque Country. All patients joining the cohort met four ACR criteria [12] . Patients are routinely assessed every 36 months unless clinical status requires more frequent visits. Patients on long-term remission are seen on a yearly basis. At each visit, clinical, laboratory and treatment data are incorporated into our database. All patients joining the Lupus-Cruces cohort gave informed consent. The local institutional review board of the Hospital Universitario Cruces approved the study in compliance with the Declaration of Helsinki. Among the 305 patients included in the cohort at the time of this study, 53 patients were excluded because their follow-up was <5 years and 22 patients because data were insufficient to calculate the cumulative prednisone dose, most of them because the diagnosis was made in other centres. Thus the final number of patients included in the study was 230.
Damage and activity evaluation
Damage was calculated using the SDI [10] . The first SDI score was calculated 6 months after the diagnosis of SLE, as per definition. Damage at this point was designated as early damage. SDI scores were then calculated on a yearly basis. The following damage-related variables were used for the analysis: any damage at 5 years (yes/ no categorical variable), SDI absolute score at 5 years (SDI-5) and SDI variation between baseline and 5 years (SDI 15), the latter accounting for new damage. According to the definition of irreversible damage, SDI scores can never decrease over time [10] .
In order to analyse specific damage attributable to glucocorticoids, the following SDI subcategories were selected: avascular osteonecrosis, osteoporotic fractures, diabetes mellitus and cataracts. Cardiovascular damage domains were not chosen, given the potential influence of clinical and therapeutic variables other than glucocorticoids. Patients with early damage in any of these domains (n = 5) were excluded from this subanalysis. In order to adjust for lupus activity we used the mean SLEDAI score [13] during years 14.
Assessment of glucocorticoid use
Prednisone cumulative doses were calculated from the information contained in our database, completed with data from the medical notes if needed. The mean dose in two consecutive visits was calculated and multiplied by the period of time between them. The cumulative dose was obtained in this way and calculated on a yearly basis.
For the purposes of this study we used the dose of prednisone received by the end of the fourth year of follow-up (hence denominated prednisone-4), just before the point when damage at 5 years could be first counted. The absolute amount (in milligrams) obtained was transformed into the average daily dose (mg/day) by dividing by the total number of days of follow-up (1461.6 days in 4 years).
In addition, a categorical variable, the prednisone-4 dose categories, was created according to the classification by Buttgereit et al. [2] , based on the degree of saturation of the different glucocorticoid receptors implicated in the genomic and non-genomic pathways. The average daily prednisone dose was thus divided into low dose (47.5 mg/day), medium dose (430 mg/day) and high dose (>30 mg/day), however, given the small number of patients on a high average daily dose of prednisone-4 (n = 5), medium and high categories were grouped for the purposes of this study. Thus there were three prednisone-4 dose categories: no prednisone, low dose and mediumhigh dose. The same categorical variable was created for the average dose of prednisone received up to the end of the first year (prednisone-1 dose categories). This variable was used as a surrogate of prednisone-4 and was only used for the time-dependent analysis (see next section). Finally, the total dose of i.v. methylprednisolone in 4 years was also calculated.
Statistical analysis
Descriptive data were generated, using percentages, means and S.D.s. Univariate comparisons were made using chi-square test, Fisher's exact test or non-paired Student's t-test, as appropriate. Linear regression was used to test the associations between SDI-5, SDI 15 and prednisone-4 dose. To analyse the relationship of these final variables and prednisone-4 dose categories, analysis of variance (ANOVA) with Bonferroni's post hoc analysis was used.
The associations between the average daily prednisone-4 dose and both SDI-5 and SDI 15 were adjusted by means of multiple linear regression for variables potentially related to irreversible damage [1417]: gender, age at SLE diagnosis, calendar year of diagnosis, mean SLEDAI, presence of early damage, presence of proliferative LN and months on antimalarials by the fifth year of follow-up. The same adjusting variables were used to test the association of any damage accrual at year 5 with prednisone-4 dose categories by means of logistic regression. In order to study the effect of i.v. pulses of methylprednisolone on damage accrual, the same analyses with the same adjusting variables were made using the www.rheumatology.oxfordjournals.org total methylprednisolone dose in 4 years instead of prednisone-4 variables.
With regard to the association of prednisone-4 dose category and the development of glucocorticoid-attributed damage at 5 years, adjustment was made by gender, age at diagnosis, calendar year of diagnosis, aPL and months on calcium plus vitamin D by the end of the fourth year, all potentially influencing the risk of osteoporotic fractures, osteonecrosis, cataracts and/or diabetes mellitus [3] .
We also analysed the time-dependent effects of prednisone on first damage accrual. Therefore patients with early damage (n = 42) were excluded from this analysis. The remaining 188 patients were divided into four groups according to prednisone-1 dose category (no prednisone, low, medium or high dose). Free-of-damage cumulative survival rates up to year 5 were calculated for each dose category and compared by means of the logrank test. A time to first damagedependent Cox regression was built, with prednisone-1 dose category as the main independent variable and gender, age at diagnosis, calendar year of diagnosis and mean SLEADI at year 1 as adjustment variables.
Results
Baseline features and drug therapy during follow-up
Two hundred and thirty patients were included in the study. Baseline demographic and clinical variables are shown in Table 1 . By the end of the fourth year of follow-up, 188 patients (82%) had been treated with oral prednisone. Prednisone-4 variables are shown in Table 2 . During the 4-year follow-up, antimalarials were ever used by 118 patients (51%), 20 patients (9%) were treated with CYC, 49 patients (21%) ever received AZA, 12 patients (5%) were treated with MTX and 9 patients (4%) received MMF.
Damage
Forty-two patients (18.3%) had early damage. This number increased to 87 (37.8%) at 5 years. The mean SDI increased from 0.23 at baseline to 0.62 at year 5 (P < 0.001). The distribution of damage by specific SDI domain is shown in Table 3 .
Prednisone-4 and damage at year 5
Compared with patients with no damage, patients with any damage at year 5 had received a higher cumulative prednisone-4 dose (15.3 vs 8.9 g) and a higher mean daily prednisone-4 dose (10.4 vs 6 mg/day) (P < 0.001 for both comparisons) ( Table 4 ). Statistically significant associations were found between the average daily prednisone-4 dose and both SDI-5 (P = 0.001) and SDI 15 (P = 0.02). By the end of year 5, damage was accrued by 9/42 (21%) patients on no prednisone, 29/96 (30%) of those on low doses and 49/92 (53%) of those receiving mediumhigh doses of prednisone-4 (P < 0.001). Prednisone-4 dose category was statistically related to both SDI-5 (P = 0.008) and SDI 15 (0.012). In the post hoc analyses, significant differences for SDI-5 and SDI 15 were seen between no prednisone and mediumhigh doses (P = 0.013 and 0.02, respectively). Statistical trends were found between low and mediumhigh doses (P = 0.07 and P = 0.08, respectively).
Damage attributable to glucocorticoids
Eighteen patients developed new damage attributable to glucocorticoids: cataracts in 6 patients, osteoporotic fractures in 7 patients, avascular necrosis in 4 patients and diabetes mellitus in 2 patients. One patient accrued damage in two domains.
The mean prednisone-4 cumulative dose and the mean average daily prednisone-4 dose were higher in patients accruing damage attributable to glucocorticoids compared with those with no damage: 16.4 vs 10.5 g and 11 vs 7 mg/day, respectively (P = 0.04 for both comparisons) ( Table 4 ). The analysis using prednisone-4 dose category yielded similar results: damage attributable to glucocorticoids was present in 1/41 (2.5%) patients on no prednisone, in 4/96 (4%) of those on low doses and in 13/88 (15%) of those on mediumhigh doses (P = 0.01).
The four patients who suffered osteonecrosis had received average daily doses of prednisone > 7.5 mg/day up to the time of the occurrence of the event (13, 14, 18 and 37 mg/day, respectively). Similar data were seen in six of seven patients suffering osteoporotic fractures (8.6, 12, 15, 19, 28 and 60 mg/day), with only a 63-year-old woman receiving a mean dose of 6.2 mg/day over 3 years. All patients with cataracts also received prednisone at medium average doses (8.4, 8.6, 10, 13 and 30 mg/day, respectively) except for a 74-year-old woman who suffered this complication during the first year of follow-up. Only one of the two cases with diabetes was treated with prednisone, at a mean dose of 45 mg/day.
Multivariable analysis
The effect of the average daily prednisone-4 dose on SDI-5 persisted after adjusting for gender, age at diagnosis, calendar year of diagnosis, mean SLEDAI, presence of early damage, proliferative nephritis and cumulative months on antimalarials by year 5 (adjusted R 2 = 0.51, P = 0.009). Similar results were obtained for the dependent variable SDI 15 (adjusted R 2 = 0.14, P = 0.009). Patients taking mediumhigh doses of prednisone-4 had a higher risk of accruing damage than those taking no prednisone [adjusted odds ratio (OR) 5.39, 95% CI 1.59, 18 .27]; no differences were seen between the latter and patients on low prednisone-4 doses (adjusted OR 1.65, 95% CI 0.53, 5.10) ( Table 5 ).
In damage attributable to glucocorticoids, the mean daily prednisone-4 dose was a significant independent predictor after adjusting for gender, age at diagnosis, cumulative months on vitamin D treatment, aPL positivity and calendar year of diagnosis (adjusted OR 1.07, 95% CI 1.01, 1.13). Likewise, patients taking mediumhigh doses accrued damage attributable to glucocorticoids more frequently than patients on no prednisone (adjusted OR 9.9, 95% CI 1.1, 84), while no differences were seen between patients receiving low doses and those on no prednisone treatment (adjusted OR 1.7, 95% CI 0.17, 17) ( Table 5 ).
Survival analysis
Among the 188 patients without early damage, 50 patients (27%) received no prednisone, 43 patients (23%) were treated with low doses, 81 patients (43%) with medium doses and 14 patients (7%) with high doses. There was a significant correlation between prednisone-1 and prednsione-4 dose categories (McNemar test, P < 0.001). The mean daily dose of prednisone-4 was 1.2, 4.4, 9.5 and 22.1 mg/day, respectively, in patients on no prednisone, low, medium and high prednisone-1 doses (P < 0.001).
Forty-five patients (24%) accrued damage within the first 5 years of follow-up. The cumulative free-of-damage survival in patients treated with no prednisone, low, medium and high doses was 86%, 73%, 64% and 44%, respectively (P = 0.008) (Fig. 1) . Compared with patients on no prednisone, a significantly higher risk of accruing damage was seen among patients treated with high doses of prednisone-1 [adjusted hazard ratio (HR) 7.2, 95% CI 2.2, 23.1] and a borderline trend among those on medium doses (adjusted HR 2.4, 95% CI 0.96, 6.2). In contrast, the risk was not higher for patients treated with low doses of prednisone-1 (adjusted HR 1.7, 95% CI 0.60, 4.87).
Methylprednisolone and damage
The cumulative dose of i.v. methylprednisolone-4 was not associated with either the absolute SDI score or the SDI 15 after adjusting for age at SLE diagnosis, calendar year of diagnosis, gender, mean maximum SLEDAI, presence of early damage, presence of proliferative LN and months on antimalarials by the fifth year of follow-up (P = 0.94 in 
Discussion
Our results confirm that prednisone is associated with damage accrued within the first 5 years following the diagnosis of SLE. A threshold has been identified, since average doses of prednisone >7.5 mg/day were associated with damage accrual and doses <7.5 mg/day were not. Irreversible organ damage is a primary outcome in SLE. It is accrued during the course of lupus, not only caused by the disease itself, but also by therapy. The SDI, divided into 38 items grouped in 12 organ systems, quantifies damage [9] and has been found to be a strong predictor of mortality [18] . In 2004 we reported that patients in the Lupus-Cruces cohort with a 1-year SDI >1 had lower long-term survival rates [19] . Decreased quality of life and increased economic burden have both been associated with damage [20] . Therefore preventing organ damage accrual should be one of the main objectives of lupus therapy, far beyond controlling SLE activity.
The relationship between glucocorticoids and damage has been investigated by several groups. In 1998 Nossent et al. [21] analysed the association of damage with corticosteroid therapy in a cohort of 90 Afro-Caribbean patients. The mean SDI scores were similar in corticosteroid users vs non-users (2.7 vs 2.04, respectively) and patients who received high prednisone doses did not accrue more damage than those who did not. The small sample size, the specific geographic location (Netherlands Antilles) and the very low survival rates of the cohort (62% at 10 years, 52% at 15 years) made it difficult to generalize these results.
In 2000, Zonana-Nacach et al. [4] analysed the effect of glucocorticoids on damage in the Hopkins Lupus Cohort. Adjusted by gender, age at diagnosis, weeks on vitamin D at the end of fourth year, aPL and calendar year of diagnosis. OR: odds ratio; prednisone-4: prednisone at the end of the fourth year of follow-up. Using a time-dependent model adjusted by gender, race and age at diagnosis, the cumulative glucocorticoid dose was associated with specific permanent organ damage: osteoporotic fractures, avascular necrosis, cataracts, coronary artery disease and diabetes mellitus. A subsequent analysis showed that the cumulative prednisone dose maintained the association with osteoporotic fractures, coronary artery disease and cataracts while the risk of avascular necrosis and stroke was dependent on high prednisone doses.
The same group created a weighted model some years later [5] . The risk of damage accrual increased with the cumulative prednisone dose, even after adjusting for multiple variables, including baseline SLE activity. Such risk tended to increase from the equivalent to 6 mg/day. This study did not analyse specific subtypes of damage.
In 2003, Gladman et al. [6] studied damage accrual patterns in an inception cohort of 73 patients during the first 15 years of follow-up. They identified SDI domains that could be related to prednisone use by creating three categories: definitely, possibly or not related. The contribution of prednisone to damage was lower in early disease, increasing over time and constituting the highest burden of damage at 15 years. The musculoskeletal domain was the most frequently scored domain, followed by the cardiovascular and neuropsychiatric domains.
Confounding by indication has been claimed as a limitation to attributing damage accrual to glucocorticoids. However, and despite one isolated link with vertebral fractures [22] , methylprednisolone pulses, usually given to patients with high activity, have not been associated with increased damage [4] , and were not associated in this study. The inclusion in multivariable models of activity-related variables such as SLEDAI, use of immunosuppressive drugs or specific organ involvement can also contribute to minimize the influence of confounding by indication.
This study has a number of limitations. First, this is an observational cohort study, with treatments prescribed at the discretion of the attending physicians. Twenty-two patients from the cohort had to be excluded from the study due to lack of enough data to calculate prednisonerelated variables. Second, our cohort was almost entirely composed of Caucasians with full access to public health care, and therefore with a potential better prognosis than other groups of different ethnic/geographic origin. Indeed, the mean SDI at the fifth year of follow-up was somewhat lower in our patients than in those from the Toronto cohort (0.62 vs 0.8) [8] . Third, we performed an analysis of damage at 5 years of follow-up, looking for associations with prednisone received up to that point. However, some patients accrued damage earlier, with the consequent miscalculation of the prednisone dose received up to the time of actual damage accrual. Fourth, we analysed damage accrued within 5 years after the diagnosis of SLE, a time of observation that may not be long enough to assess the predictors of damage that might appear later in the disease course, like cardiovascular domains. Fifth, the analysis of damage associated with methylprednisolone may be somewhat conditioned by the usual prescription in our unit of pulses 4500 mg. Thus, whether higher doses of 1 g can cause damage accrual, as well as other side effects such as infections [23] , cannot be addressed from our results.
On the other hand, this study has important strengths. We have analysed not only the presence of damage accrued as a dichotomized variable, but also quantified it by using the SDI. For the first time, new damage after the initial 6-month assessment and new glucocorticoidattributable damage have been used as outcomes in order to analyse damage accrued after the initiation of steroid therapy. It is well known that patients with damage tend to accrue more damage, thus the variable early damage was used to control for this in the multivariate analyses. Other adjustment variables were included, such as those related to disease activity/ severity, gender, age, calendar year of diagnosis and treatment with antimalarials. A number of different variables have been constructed to analyse the effects of glucocorticoids. A time-dependent analysis using the surrogate variable average daily prednisone-1 has been included in order to overcome the potential bias of damage accrued before the fifth year of follow-up. All the analyses performed led to the same point: long-term prednisone at average doses >7.5 mg/day can cause irreversible organ damage in lupus.
Damage caused by glucocorticoids is generally believed to be the inevitable price to pay for controlling lupus activity. However, this assumption is based on custom rather than on solid evidence [3] . In a recent study by our group, a medium-dose prednisone-based regime was compared with a high-dose prednisone, NIH-based protocol for the induction therapy of biopsyproven LN [24] . In the former regimen, prednisone was rapidly tapered and combined with pulse methylprednisolone, HCQ and CYC. This therapy resulted in an average prednisone dose at 6 months of 9 mg/day, compared with 25 mg/day in the high-dose regime. Toxicity was significantly lower, including metabolic side effects, osteonecrosis and osteoporotic fractures, and, remarkably, the medium-dose regimen resulted in a more rapid and sustained renal response, with 100% of patients eventually achieving complete response vs 70% of patients treated with high doses. Other groups have reported good response of LN to regimens using doses of prednisone <20 mg/day [7] or even to oral steroid-free protocols including rituximab and MMF [25] .
Every effort should be made to minimize the unwanted effects of prednisone without giving up the huge antiinflammatory potential of glucocorticoids. The use of pulse therapy instead of high oral doses in periods of disease activity, the early association of immunosuppressive drugs and the universal baseline therapy with HCQ are simple measures that can contribute to the goal of discontinuing prednisone or, at least, using it at low doses. We should always keep in mind that one of the main commitments to our patients is not causing with www.rheumatology.oxfordjournals.org our interventions more harm than the disease we are aiming to treat.
Rheumatology key messages
. Prednisone therapy is associated with damage accrual in patients with SLE. . Doses of prednisone <7.5 mg/day do not cause global or glucocorticoid-related damage in patients with SLE. . Methylprednisolone pulses are not related to new damage accrual in patients with lupus.
